# YCANTH (cantharidin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cantharidin

> The FDA approved YCANTH (cantharidin), sponsored by Verrica Pharmaceuticals Inc. (VRCA), on July 21, 2023 for molluscum contagiosum and began capitalizing inventory purchases of saleable product.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is YCANTH (cantharidin) FDA approved?

Yes. The FDA approved YCANTH (cantharidin), sponsored by Verrica Pharmaceuticals Inc. (VRCA), on July 21, 2023 for molluscum contagiosum and began capitalizing inventory purchases of saleable product. SEC Form 10-K: "On July 21, 2023, the Company received FDA approval for YCANTH (VP-102) for the treatment of molluscum and began capitalizing inventory purchases of saleable product from certain suppliers." [Calendar and source filings](https://sec-api.dev/pdufa/cantharidin)

Source: SEC Form 10-K, accession 0001660334-26-000008, https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-03-11. Cite: https://sec-api.dev/pdufa/cantharidin#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | YCANTH (cantharidin) |
| Codes | VP-102 |
| Sponsor | Verrica Pharmaceuticals Inc. (VRCA) https://sec-api.dev/companies/vrca/catalysts |
| Indications | common warts, molluscum contagiosum and began capitalizing inventory purchases of saleable product, molluscum, molluscum and began capitalizing inventory purchases of saleable product, common warts in december 2025, and company expects to initiate the second phase 3 study, molluscum contagiosum in adult and pediatric patients two years of age and older, Common Warts (Verruca Vulgaris) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 13, 2020: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22212905_2024_Orig1s000OtherActionLtrs.pdf%22

### Feb 2021: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2024-11-20, last confirmed 2024-11-21.
- SEC prospectus (424B) (accession 0001193125-24-263473): "In February 2021, we received notice that the FDA accepted the resubmitted NDA for filing, with a PDUFA goal date of June 23, 2021." https://www.sec.gov/Archives/edgar/data/1660334/000119312524263473/d817723d424b5.htm
- SEC prospectus (424B) (accession 0001193125-24-262611): "In February 2021, we received notice that the FDA accepted the resubmitted NDA for filing, with a PDUFA goal date of June 23, 2021." https://www.sec.gov/Archives/edgar/data/1660334/000119312524262611/d817723d424b5.htm

### September 16, 2021: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2024-11-20, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22212905_2024_Orig1s000OtherActionLtrs.pdf%22
- SEC prospectus (424B) (accession 0001193125-24-263473): "Following the CRL, on September 22, 2021 we received a General Advice Letter from the FDA with recommendations to improve VP-102s user interface." https://www.sec.gov/Archives/edgar/data/1660334/000119312524263473/d817723d424b5.htm
- SEC prospectus (424B) (accession 0001193125-24-262611): "Following the CRL, on September 22, 2021 we received a General Advice Letter from the FDA with recommendations to improve VP-102s user interface." https://www.sec.gov/Archives/edgar/data/1660334/000119312524262611/d817723d424b5.htm

### November 29, 2021: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: molluscum.
- First seen 2024-11-20, last confirmed 2024-11-21.
- SEC prospectus (424B) (accession 0001193125-24-263473): "With the satisfactory resolution of the facility inspection, we resubmitted the NDA for the approval of VP-102 for the treatment of molluscum on November 29, 2021." https://www.sec.gov/Archives/edgar/data/1660334/000119312524263473/d817723d424b5.htm
- SEC prospectus (424B) (accession 0001193125-24-262611): "With the satisfactory resolution of the facility inspection, we resubmitted the NDA for the approval of VP-102 for the treatment of molluscum on November 29, 2021." https://www.sec.gov/Archives/edgar/data/1660334/000119312524262611/d817723d424b5.htm

### December 15, 2021: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2024-11-20, last confirmed 2024-11-21.
- SEC prospectus (424B) (accession 0001193125-24-263473): "On December 15, 2021 the FDA accepted our NDA resubmission for VP-102 and assigned a new PDUFA goal date of May 24, 2022." https://www.sec.gov/Archives/edgar/data/1660334/000119312524263473/d817723d424b5.htm
- SEC prospectus (424B) (accession 0001193125-24-262611): "On December 15, 2021 the FDA accepted our NDA resubmission for VP-102 and assigned a new PDUFA goal date of May 24, 2022." https://www.sec.gov/Archives/edgar/data/1660334/000119312524262611/d817723d424b5.htm

### May 23, 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22212905_2024_Orig1s000OtherActionLtrs.pdf%22

### July 21, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: molluscum contagiosum and began capitalizing inventory purchases of saleable product.
- First seen 2024-11-20, last confirmed 2026-03-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-262615): "VP-102), was approved by the U.S. Food and Drug Administration, or FDA, in July 2023 for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older." https://www.sec.gov/Archives/edgar/data/1660334/000119312524262615/d907739dex992.htm
- SEC Form 10-K (accession 0001660334-26-000008): "On July 21, 2023, the Company received FDA approval for YCANTH (VP-102) for the treatment of molluscum and began capitalizing inventory purchases of saleable product from certain suppliers." https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm
- SEC Form 10-Q (accession 0000950170-25-070452): "On July 21, 2023, the Company received FDA approval for YCANTH (VP-102) for the treatment of molluscum contagiosum and began capitalizing inventory purchases of saleable product from certain suppliers." https://www.sec.gov/Archives/edgar/data/1660334/000095017025070452/vrca-20250331.htm
- SEC Form 10-K (accession 0000950170-25-037172): "On July 21, 2023, the Company received FDA approval for YCANTH (VP-102) for the treatment of molluscum contagiosum and began capitalizing inventory purchases of saleable product from certain suppliers." https://www.sec.gov/Archives/edgar/data/1660334/000095017025037172/vrca-20241231.htm
- SEC Form 10-K (accession 0001660334-26-000008): "YCANTH (VP-102), which was approved by the FDA for treatment of molluscum in July 2023, is our only approved product and became commercially available in August 2023." https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm
- SEC Form 10-K (accession 0000950170-25-037172): "YCANTH (VP-102), which was approved by the FDA for treatment of molluscum contagiosum in July 2023, is our only approved product and became commercially available in August 2023." https://www.sec.gov/Archives/edgar/data/1660334/000095017025037172/vrca-20241231.htm

### January 7, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 3. Indication: common warts in December 2025, and Company expects to initiate the second Phase 3 study.
- First seen 2026-03-11, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219395): "On January 7, 2026, the Company announced that the first patient was dosed in December 2025 in the first trial (COVE-2) of our global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts." https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529dex991.htm
- SEC Form 10-K (accession 0001660334-26-000008): "We are also advancing YCANTH (VP-102) for common warts through a separate regulatory approval process and have initiated a global Phase 3 study, or the Program, in common warts with our partner, Torii, with first patient dosed in December 2025." https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-101126): "- First patient dosed in the first Phase 3 study of YCANTH for the treatment of common warts in December 2025, and Company expects to initiate the second Phase 3 study in the US and Japan with Torii Pharmaceutical in mid-2026 -" https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/d94203dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-101126): "On January 7, 2026, the Company announced that the first patient was dosed in December 2025 in the global" https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/d94203dex991.htm
- SEC Form 10-Q (accession 0001660334-26-000030): "One-third of the shares underlying the warrant vested in December 2025, when the first patient was dosed in the Program, with the remaining vesting occurring one-third on the date that the database lock with respect to the trial occurs and one-third on the date the Company submits a new drug application to the FDA for YCANTH (VP-102) for the treatment of common warts." https://www.sec.gov/Archives/edgar/data/1660334/000166033426000030/vrca-20260930.htm
- SEC Form 10-Q (accession 0001660334-26-000025): "One-third of the shares underlying the warrant vested in December 2025, when the first patient was dosed in the Program, with the remaining vesting occurring one-third on the date that the database lock with respect to the trial occurs and one-third on the date the Company submits a new drug application to the FDA for YCANTH (VP-102) for the treatment of common warts." https://www.sec.gov/Archives/edgar/data/1660334/000166033426000025/vrca-20260630.htm
- SEC Form 10-Q (accession 0001660334-26-000014): "One-third of the shares underlying the warrant vested in December 2025, when the first patient was dosed in the Program, with the remaining vesting occurring one-third on the date that the database lock with respect to the Trial occurs and one-third on the date the Company submits a new drug application to the FDA for YCANTH (VP-102) for the treatment of common warts." https://www.sec.gov/Archives/edgar/data/1660334/000166033426000014/vrca-20260331.htm
- SEC Form 10-K (accession 0001660334-26-000008): "Table of Contents warrant vested in December 2025 when the first patient was dosed in the Program, and the remaining vesting will occur one-third on the date that the database lock with respect to the Program occurs and one-third on the date we submit an NDA to the FDA for YCANTH (VP-102) for the treatment of common warts." https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm
- SEC Form 10-K (accession 0001660334-26-000008): "One-third of the shares underlying the warrant vested in December 2025, when the first patient was dosed in the Program, with the remaining vesting occurring one-third on the date that the database lock with respect to the Trial occurs, and one-third on the date the Company submits a new drug application to the FDA for YCANTH (VP-102) for the treatment of common warts." https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm

### May 12, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 3. Indication: common warts.
- First seen 2026-05-12, last confirmed 2026-05-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219395): "Further, last December the first patient was dosed in the first trial (COVE-2) of the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts, and we are happy to announce achievement of over 50% of the current targeted enrollment in the trial." https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529dex991.htm

### mid-2027: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338273): "Based upon current projections, the Company expects to present topline data from the program in mid-2027." https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338273): "- Topline data from global Phase 3 program studying common warts currently expected in mid-2027 -" https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338273): "Topline data from our global Phase 3 program is currently expected in mid-2027, as our studies are recruiting well." https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828dex991.htm

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07457918 (Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." https://clinicaltrials.gov/study/NCT07457918

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07457918 (Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." https://clinicaltrials.gov/study/NCT07457918

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cantharidin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "YCANTH (cantharidin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cantharidin

```bibtex
@misc{secapidev_pdufa_cantharidin_20261116,
  title        = {YCANTH (cantharidin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cantharidin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cantharidin_20261116","title":"YCANTH (cantharidin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cantharidin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
